These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 20153253)

  • 1. The immunobiology of aluminium adjuvants: how do they really work?
    Exley C; Siesjö P; Eriksson H
    Trends Immunol; 2010 Mar; 31(3):103-9. PubMed ID: 20153253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation.
    Hem SL; Hogenesch H
    Expert Rev Vaccines; 2007 Oct; 6(5):685-98. PubMed ID: 17931150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. (How) do aluminium adjuvants work?
    Brewer JM
    Immunol Lett; 2006 Jan; 102(1):10-5. PubMed ID: 16188325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Vaccination--new facts from basic research].
    Dalpke AH
    MMW Fortschr Med; 2010 Jul; 152 Suppl 2():42-6. PubMed ID: 21591318
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanism of immunopotentiation by aluminum-containing adjuvants elucidated by the relationship between antigen retention at the inoculation site and the immune response.
    Noe SM; Green MA; HogenEsch H; Hem SL
    Vaccine; 2010 Apr; 28(20):3588-94. PubMed ID: 20211692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of C-reactive protein as an inflammatory biomarker in rabbits for vaccine nonclinical safety studies.
    Destexhe E; Prinsen MK; van Schöll I; Kuper CF; Garçon N; Veenstra S; Segal L
    J Pharmacol Toxicol Methods; 2013; 68(3):367-73. PubMed ID: 23624216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Towards an understanding of the adjuvant action of aluminium.
    Marrack P; McKee AS; Munks MW
    Nat Rev Immunol; 2009 Apr; 9(4):287-93. PubMed ID: 19247370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody and T-cell responses to a virosomal adjuvanted H9N2 avian influenza vaccine: impact of distinct additional adjuvants.
    Radosević K; Rodriguez A; Mintardjo R; Tax D; Bengtsson KL; Thompson C; Zambon M; Weverling GJ; Uytdehaag F; Goudsmit J
    Vaccine; 2008 Jul; 26(29-30):3640-6. PubMed ID: 18514980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of dendritic cells and induction of CD4(+) T cell differentiation by aluminum-containing adjuvants.
    Sokolovska A; Hem SL; HogenEsch H
    Vaccine; 2007 Jun; 25(23):4575-85. PubMed ID: 17485153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mechanism of action of glatiramer acetate treatment in multiple sclerosis.
    Racke MK; Lovett-Racke AE; Karandikar NJ
    Neurology; 2010 Jan; 74 Suppl 1():S25-30. PubMed ID: 20038760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights for practice: where mechanism of action meets patient management.
    Lisak RP; Korngold S
    Neurology; 2010 Jan; 74 Suppl 1():S70-3. PubMed ID: 20038766
    [No Abstract]   [Full Text] [Related]  

  • 12. Aluminium adjuvants--in retrospect and prospect.
    Lindblad EB
    Vaccine; 2004 Sep; 22(27-28):3658-68. PubMed ID: 15315845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative study of the effects of aluminum adjuvants and Freund's incomplete adjuvant on the immune response to an Edwardsiella tarda major antigen.
    Jiao XD; Cheng S; Hu YH; Sun L
    Vaccine; 2010 Feb; 28(7):1832-7. PubMed ID: 20006568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Unmet needs in modern vaccinology: adjuvants to improve the immune response.
    Leroux-Roels G
    Vaccine; 2010 Aug; 28 Suppl 3():C25-36. PubMed ID: 20713254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
    Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
    Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Guide to IL-1 family cytokines in adjuvanticity.
    Muñoz-Wolf N; Lavelle EC
    FEBS J; 2018 Jul; 285(13):2377-2401. PubMed ID: 29656546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation.
    Mannhalter JW; Neychev HO; Zlabinger GJ; Ahmad R; Eibl MM
    Clin Exp Immunol; 1985 Jul; 61(1):143-51. PubMed ID: 3876178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of five adjuvants on the antibody response to influenza virus antigen in guinea pigs.
    Robuccio JA; Griffith JW; Chroscinski EA; Cross PJ; Light TE; Lang CM
    Lab Anim Sci; 1995 Aug; 45(4):420-6. PubMed ID: 7474883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insight into the cellular fate and toxicity of aluminium adjuvants used in clinically approved human vaccinations.
    Mold M; Shardlow E; Exley C
    Sci Rep; 2016 Aug; 6():31578. PubMed ID: 27515230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Type I interferons as mediators of immune adjuvants for T- and B cell-dependent acquired immunity.
    Prchal M; Pilz A; Simma O; Lingnau K; von Gabain A; Strobl B; Müller M; Decker T
    Vaccine; 2009 Dec; 27 Suppl 6():G17-20. PubMed ID: 20006134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.